Machina Capital S.A.S. Acquires 33,113 Shares of Gilead Sciences, Inc. $GILD

Machina Capital S.A.S. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 33,113 shares of the biopharmaceutical company’s stock, valued at approximately $4,935,000. Gilead Sciences makes up 0.6% of Machina Capital S.A.S.’s investment portfolio, making the stock its 28th largest position.

A number of other hedge funds have also recently modified their holdings of the business. Client 1ST Advisory Group LLC lifted its position in Gilead Sciences by 4.0% during the 3rd quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 69 shares during the period. Bfsg LLC boosted its stake in Gilead Sciences by 7.7% during the third quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 72 shares in the last quarter. Grove Bank & Trust boosted its stake in Gilead Sciences by 1.2% during the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock worth $946,000 after acquiring an additional 74 shares in the last quarter. Wilkerson Advisory Group LLC boosted its stake in Gilead Sciences by 54.2% during the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares in the last quarter. Finally, HBW Advisory Services LLC grew its holdings in Gilead Sciences by 2.4% in the first quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock worth $473,000 after purchasing an additional 79 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of analyst reports. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research note on Friday, October 30th. Jefferies Financial Group set a $196.00 target price on shares of Gilead Sciences in a report on Wednesday, November 4th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $170.15.

Gilead Sciences Stock Down 0.7%

Shares of Gilead Sciences stock opened at $169.73 on Thursday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The stock has a market capitalization of $210.52 billion, a PE ratio of -53.71 and a beta of 0.35. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $176.58. The company has a 50-day simple moving average of $154.40 and a two-hundred day simple moving average of $141.51.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter in the prior year, the firm posted $2.47 earnings per share. The business’s revenue was up 6.8% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences, Inc. will post -0.98 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is presently -103.80%.

Insider Buying and Selling

In other Gilead Sciences news, EVP Wettan Keeley M. Cain sold 3,399 shares of the stock in a transaction on Friday, November 6th. The stock was sold at an average price of $164.11, for a total transaction of $557,809.89. Following the sale, the executive vice president directly owned 5,360 shares in the company, valued at approximately $879,629.60. This trade represents a 38.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 102,619 shares of Gilead Sciences stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $175.16, for a total value of $17,974,744.04. Following the completion of the sale, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at approximately $96,632,794.28. The trade was a 15.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 242,709 shares of company stock worth $39,503,427 over the last 90 days. 0.30% of the stock is currently owned by company insiders.

Top Gilead Sciences Stories

Here are a few of the latest stories about GILD:

• Positive Sentiment: Gilead reported PURPOSE 5 results showing twice-yearly injectable lenacapavir outperformed daily oral HIV prevention on persistence, with no HIV infections in the injectable group. The findings could strengthen the long-term opportunity for its HIV prevention franchise. Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Positive Sentiment: Recent coverage also points to clinical progress in HIV and liver disease and raised full-year guidance, supporting confidence in Gilead’s outlook. Its latest reported quarter beat analyst estimates for earnings and revenue, with revenue up year over year. Gilead Sciences After Trial Wins And Raised Guidance Looks Fully Valued
• Neutral Sentiment: Gilead partner Xilio expects to provide Gilead with an option data package for efarindodekin alfa in the first half of 2027. This is a potential pipeline catalyst, but remains several months away and is dependent on future data. Xilio Therapeutics Pipeline Update

Gilead Sciences Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.